On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...

Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.

Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...